Form 424B3 Estrella Immunopharma,
Tweet
Share
E-mailhttp://archive.fast-edgar.com/20260213/AV2JJ22CLC22NT2V222M2ZY2N35TZ222Z282
Filed on: February 13, 2026
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Estrella adds Oregon Health & Science University to lymphoma trial
- Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
- Cerepeut's Lead Compound Shows How a Little-Known Mitochondrial Mechanism Fuels Neurodegeneration, and How to Stop It
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
